Core Insights - The article highlights the launch of two significant products, the Peninsula Super Cannon and Peninsula Counterclockwise, by Peninsula Medical Group, which recently received NMPA Class III medical device registration [1][3] - These products aim to address deep support and superficial repair in aesthetic medicine, utilizing advanced technology to achieve comprehensive treatment from the fascia layer to the epidermis [1][2] - The company emphasizes its commitment to making advanced medical equipment accessible to thousands of hospitals in China, which were previously dominated by international giants [1] Product Innovations - The Peninsula Golden Microneedle introduces dynamic layered treatment technology, allowing for targeted treatment across five skin layers with a single needle insertion, addressing uneven energy distribution and enhancing patient comfort [2] - The Peninsula Counterclockwise, as the first domestic Class III radiofrequency microneedle, resolves the industry challenge of balancing efficacy and comfort through multi-dimensional technological innovations [2] - The Peninsula Super Cannon, the first globally to receive NMPA Class III certification for focused ultrasound skin treatment, boasts a 50% efficiency improvement and integrates high-resolution ultrasound imaging with treatment processes [3] Market Position and Growth - China is identified as the fastest-growing market for photonic anti-aging treatments, with ultrasound and radiofrequency microneedles accounting for over 60% of the market share [4] - Following its certification, the Peninsula Super Cannon experienced a surge in search interest, indicating strong market potential and consumer engagement [4] - The company has also secured multiple international certifications, including FDA and CE, positioning itself to compete on a global scale and potentially lead in the medical aesthetic device market [4]

Core Insights - The article highlights the launch of two new medical devices, Peninsula Super Cannon and Peninsula Counterclockwise, which have received NMPA Class III medical device registration and are now certified by FDA and CE, marking a significant step for the company in the global aesthetic medical market [1][2] Company Overview - Peninsula Medical, founded by Lei Xiaobing, aims to make advanced medical equipment affordable for thousands of hospitals in China that were previously dominated by international giants [1] - The company has expanded from Chongqing to Shanghai and finally established its base in Shenzhen, with products now sold in over 70 countries and regions, serving thousands of hospitals and aesthetic institutions [1] - The company boasts a research and development team of nearly 400 people, bridging clinical needs with engineering technology [1] Product Innovations - The Peninsula Super Cannon integrates a high-resolution intelligent ultrasound imaging system with treatment processes, introducing the SOP 3.0 precision treatment system, which allows for visual, quantifiable, and traceable treatment standards [2] - The Peninsula Counterclockwise, as the first domestic Class III radiofrequency microneedle device, addresses the industry pain point of balancing efficacy and comfort, utilizing multi-dimensional technological innovations [2] - Key features of the Peninsula Counterclockwise include layered treatment technology, mixed mode output, and a significant increase in energy delivery efficiency, which enhances patient comfort and reduces recovery time [2] Market Potential - According to third-party market research firm, Sullivan, China has become the fastest-growing market for photonic anti-aging treatments, with ultrasound and radiofrequency microneedles accounting for over 60% of the market, driving core growth in the industry [3] - The company expresses confidence in the future of Chinese aesthetic medical device enterprises and service institutions becoming global brands [3]

Core Insights - Peninsula Medical is experiencing rapid growth in user trust, with over 1 user receiving anti-aging or skin rejuvenation treatments every minute, and its core products have treated over 4 million users [1] - The company launched two new products, "Peninsula Big Ultrasound" and "Peninsula Counterclockwise," both of which received the highest medical device certification in China [1] - The market for anti-aging treatments in China is rapidly expanding, with 99.7% of consumers considering anti-aging important, creating significant demand for Peninsula's new products [2] Product Performance - The "Peninsula Big Ultrasound" has gained significant market attention since its NMPA III class certification, quickly becoming a trending product on social media [2] - The product's strong market performance is evidenced by high user satisfaction and repeat purchase rates, indicating its potential as a market leader [2][3] - Clinical trials for the "Peninsula Counterclockwise" show over 96% effectiveness in scar improvement and high user satisfaction rates [5][6] Technological Advancements - The "Peninsula Counterclockwise" is the first domestic product to receive both NMPA and FDA certifications, addressing key industry challenges by balancing effectiveness and comfort [4] - The "Peninsula Big Ultrasound" features advanced technology that improves energy efficiency by over 50% compared to previous models, enhancing treatment comfort and precision [5] Industry Impact - Peninsula Medical's commitment to social responsibility is highlighted by its participation in charity auctions, setting a new record in the beauty industry [3] - The company has established a strong research and development foundation, with over 1,000 patent applications and a dedicated team of nearly 400 researchers [7] - Through training programs, Peninsula Medical has certified over 12,000 professional physicians, contributing to the overall improvement of industry standards [8] Strategic Vision - Peninsula Medical aims to lead the high-end medical aesthetics market in China and globally, focusing on long-term growth and innovation [9] - The company emphasizes the integration of scientific research and clinical practice to enhance user experience and product effectiveness [9]

Core Insights - The article highlights the significant advancements in China's medical aesthetics industry, particularly the achievements of a Shenzhen-based company in developing domestically produced ultrasound and radiofrequency medical devices that have received both NMPA and FDA certifications [1][2][3]. Group 1: Technological Breakthroughs - The first domestically produced ultrasound skin treatment device has received Class III certification, while the radiofrequency skin treatment device "Half Island Counterclockwise" is the first in China to obtain both NMPA and FDA approvals [1]. - The "Half Island Big Super Cannon" integrates various treatment handles and heads, enhancing treatment comfort and effectiveness, supported by clinical data showing an 82% effectiveness rate and 88% satisfaction rate from 204 cases [1]. - The radiofrequency microneedle device demonstrated a 96% effectiveness rate in scar improvement and a 98.75% patient satisfaction rate from 180 cases [1][2]. Group 2: Industry Evolution - Over the past 17 years, the company has transitioned from relying on foreign medical equipment to becoming a leader in the global medical aesthetics market, with a significant increase in R&D investment and patent applications [3]. - The company currently has a central R&D team of 180 members, with plans to increase the number of medical professionals to 65 by 2026, and has a notable share of global patent applications in the medical aesthetics sector [3]. - The company's ultrasound devices are now used in nearly 6,000 hospitals nationwide, and the radiofrequency microneedle has reached approximately 4,000 medical institutions, with user numbers projected to exceed 1 million by 2025 [3]. Group 3: Innovation Ecosystem - Shenzhen's innovation ecosystem has played a crucial role in the company's success, supported by policies, capital, and a rich clinical resource environment [4]. - The company has been recognized as a "national-level specialized and innovative small giant" and has received national-level intellectual property advantages, contributing to the growth of Shenzhen's high-end medical device industry [4]. - The company has published nearly 100 academic papers, with over 30 in SCI journals, and has participated in developing industry standards, promoting the standardization of the sector [4]. Group 4: Future Outlook - The year 2026 is anticipated to be pivotal for the medical aesthetics industry, focusing on compliance and high-quality development [7]. - The company emphasizes training for doctors and consumer education, with a rigorous certification system for device operation, ensuring standardized application of technology [7]. - The case reflects the broader trend of China's medical aesthetics industry evolving from imitation to innovation, aiming for international competitiveness [7].

Core Viewpoint - The article highlights the launch of two significant products by the company, namely the Peninsula Super Cannon and the Peninsula Counterclockwise, which represent advancements in domestic medical aesthetic equipment and aim to lead the industry towards standardization and global competitiveness [1][3][18]. Product Launch - The Peninsula Super Cannon is the first ultrasound skin treatment device to receive a Class III medical device registration certificate from the National Medical Products Administration (NMPA) [1]. - The Peninsula Counterclockwise is the first domestic Class III radiofrequency skin treatment device to obtain both NMPA and FDA certifications [1]. Technological Advancements - Both products are the result of years of technological innovation and rigorous clinical trials, with the Super Cannon showing an efficacy rate of over 82% in improving skin laxity and a satisfaction rate exceeding 88% three months post-treatment [5]. - The Counterclockwise demonstrated a scar improvement efficacy rate of over 96% and a satisfaction rate close to 98% three months after treatment [7]. Industry Impact - The introduction of these products is seen as a step towards standardizing the medical aesthetic equipment industry in China, which has historically been dominated by international players [11][12]. - The company has been proactive in establishing clinical standards and training programs, having trained over 9,000 certified ultrasound physicians and 3,000 certified Counterclockwise physicians [9]. Market Position - The company has positioned itself among the top six global energy source medical aesthetic equipment manufacturers, with its products sold in over 70 countries and regions [18]. - The emergence of the Super Cannon and Counterclockwise signifies a shift in the domestic market from low-end competition to high-end innovation, marking China's entry into the global competitive landscape [20]. Research and Development - The company invests over 25% of its revenue annually into research and development, employing a team of nearly 400 researchers, which constitutes about 30% of its total workforce [16]. - The company has applied for over 1,000 domestic and international patents, with more than 400 granted, establishing a strong technological moat [16].

Core Insights - Peninsula Medical has launched two significant products, the Peninsula Super Cannon and the Peninsula Counterclockwise, which are set to lead the medical aesthetics equipment industry towards standardization and represent a breakthrough for domestic technology in the global market [1][4][27]. Product Launch - The Peninsula Super Cannon is the first ultrasound skin treatment device to receive a Class III medical device registration from the Chinese National Medical Products Administration (NMPA) [1][27]. - The Peninsula Counterclockwise is the first domestic Class III radiofrequency skin treatment device to achieve dual certification from both the NMPA and the U.S. FDA [1][27]. Industry Impact - The introduction of these products is seen as a move towards standardization in the medical aesthetics industry, which is increasingly influenced by the "beauty economy" and advancements in photonic technology [5][12]. - The medical aesthetics equipment market in China has significant growth potential, with the penetration of photonic medical aesthetics technology driving the development of downstream services [16][30]. Research and Development - Peninsula Medical has invested heavily in R&D, allocating over 25% of its revenue annually, and has a dedicated R&D team of nearly 400 people, constituting 30% of its total workforce [21][27]. - The company has filed over 1,000 domestic and international patents, with more than 400 granted, establishing a strong technological moat [21]. Clinical Validation - The clinical trials for the Peninsula Super Cannon involved 204 subjects, showing an efficacy rate of over 82% in improving skin laxity, with a satisfaction rate exceeding 88% three months post-treatment [7][9]. - The clinical data for the Peninsula Counterclockwise indicated a scar improvement efficacy rate of over 96% and a satisfaction rate close to 98% three months after the procedure [9]. Market Position - Peninsula Medical has positioned itself among the top six global energy source medical aesthetics equipment companies, with its products sold in over 70 countries and regions, serving more than 10,000 well-known hospitals [27]. - The launch of these products marks a shift in the domestic medical aesthetics equipment landscape, moving from low-end market competition to achieving international certifications and recognition [27][30].

Core Viewpoint - The article highlights the rapid growth of China's medical aesthetics equipment industry, showcasing the emergence of domestic brands like Peninsula Medical, which are gaining market share and technological advancements in the field [3][19]. Industry Growth - The domestic medical aesthetics equipment market is projected to exceed 32 billion yuan by 2024, with a compound annual growth rate (CAGR) of 13%-15% [3]. - The market share of domestic equipment has increased from 38% in 2020 to 42% in 2024, with energy source segments like radiofrequency and intense pulsed light reaching a 46% share [3]. Product Innovation - Peninsula Medical's two core products, the Peninsula Ultra Cannon and Peninsula Counterclockwise, represent significant advancements in energy source medical aesthetics devices, with a focus on clinical needs and technological innovation [3][5]. - The Peninsula Ultra Cannon is the first and only ultrasound medical aesthetics device to receive NMPA Class III certification, achieving precise anti-aging treatment from the epidermis to the SMAS layer [3][5]. - The Peninsula Counterclockwise is the first domestic radiofrequency medical aesthetics device to obtain NMPA Class III certification, featuring innovative technologies for effective treatment [5][7]. Clinical Research and Efficacy - Clinical studies led by top hospitals show that the Peninsula Ultra Cannon has an effectiveness rate of over 89% in improving skin laxity, with a satisfaction rate exceeding 90% among participants [5]. - Since its launch in 2021, the Peninsula Ultra Cannon has been used in over 4 million treatments, averaging more than 3,000 treatments per day [5]. R&D and Patents - Peninsula Medical has a strong focus on R&D, with nearly 400 staff dedicated to research, accounting for 30% of total employees, and R&D investment representing 25%-27% of sales revenue [9]. - The company has filed over 1,000 domestic and international patents, with more than 70 global certifications, and has played a role in drafting industry standards [9][19]. International Expansion - The presence of Chinese dermatologists and plastic surgeons on the Nasdaq screen signifies the increasing international participation of China's medical aesthetics professionals [11]. - Peninsula Medical's collaboration with Boston Aesthetics aims to bridge the gap between Chinese R&D and U.S. clinical needs, facilitating the entry of Chinese products into the global market [12][18]. Market Trends - The export value of domestic medical aesthetics equipment is expected to grow by 35% in 2024, with energy source devices making up 42% of exports, expanding into high-end markets like Europe and the U.S. [19]. - The industry is transitioning from a focus on cost-effectiveness to differentiation, with domestic companies targeting specific needs of Asian skin types [14][19]. Future Outlook - The integration of artificial intelligence with medical aesthetics devices is emerging as a new trend, enabling personalized treatment parameters [19]. - The industry is poised for a comprehensive upgrade from "Made in China" to "Intelligent Manufacturing in China," driven by companies focused on R&D and clinical needs [19].

Core Insights - Peninsula Medical showcased its brand on the Nasdaq screen, highlighting its rapid growth in the Chinese medical aesthetics industry, with the domestic medical aesthetic equipment market projected to exceed 32 billion yuan by 2024, maintaining a compound annual growth rate of 13%-15% [1][11] - The company presented two NMPA Class III certified products, the Peninsula Ultra Cannon and Peninsula Counterclockwise, in collaboration with Boston Aesthetics and numerous Chinese dermatologists and plastic surgeons [1][2] Industry Growth - The domestic medical aesthetic equipment market is expected to grow significantly, with the share of domestic equipment increasing from 38% in 2020 to 42% in 2024, particularly in energy source segments like RF and IPL, where domestic brands now hold a 46% market share [1][11] - The clinical demand drives technological innovation, with Peninsula Medical focusing on addressing industry pain points through medical-engineering collaboration [2][3] Product Innovation - The Peninsula Ultra Cannon is the first globally to receive NMPA Class III certification for ultrasound medical aesthetics, achieving over 89% effectiveness in improving skin laxity in clinical studies [2][3] - The Peninsula Counterclockwise is the first domestic RF medical aesthetic device to receive NMPA Class III certification, featuring innovative technologies for precise depth control in clinical applications [3][4] Research and Development - Peninsula Medical has a robust R&D team of nearly 400, accounting for 30% of its workforce, with R&D investment constituting 25%-27% of sales revenue, which is high for the industry [4][5] - The company has filed over 1,000 domestic and international patents and has received more than 70 global certifications, contributing to the industry's shift from imitation to independent innovation [5][11] International Expansion - The presence of Chinese dermatologists and plastic surgeons on the Nasdaq screen signifies the increasing international participation of Chinese medical aesthetics professionals [6][11] - Peninsula Medical's Boston Aesthetics team is pivotal in bridging Chinese R&D with U.S. clinical needs, having successfully registered the Peninsula Counterclockwise in the U.S. [7][10] Market Trends - The international competitiveness of domestic devices is shifting from cost-effectiveness to differentiated advantages, focusing on the unique characteristics of Asian skin [8][9] - The export value of domestic medical aesthetic devices is projected to grow by 35% in 2024, with energy source devices making up 42% of exports, expanding into high-end markets like Europe and the U.S. [11]

Core Insights - The strategic partnership between Yuansong Group and Peninsula Medical marks the launch of China's first approved Class III ultrasonic medical beauty device, enhancing compliance in the aesthetic medicine market [1][2] - The Chinese aesthetic medicine industry has reached a market size of hundreds of billions, with the non-invasive anti-aging sector experiencing double-digit growth, despite challenges such as equipment qualification and quantifiable results [1] Group 1: Strategic Partnership - The collaboration aims to integrate Peninsula Medical's 14 years of research in developing the first Class III ultrasonic medical beauty device with Yuansong's established compliance service system [1] - The "Half Island Super Cannon" received approval for Class III medical device registration at the end of October, becoming the first ultrasonic medical beauty device in China to obtain this certification [1] Group 2: Compliance and Service - Yuansong's competitive advantage lies in the dual assurance of compliant equipment and transparent services, filling a gap in the compliant ultrasonic anti-aging service sector [2] - The company has established nearly 30 direct-operated clinics in 20 major cities, serving over one million consumers, and has formed strategic partnerships with several listed companies to promote high-standard products [2]

Core Viewpoint - The Chinese medical aesthetics device industry is entering a new development stage characterized by high standards, strong regulation, and genuine innovation, as evidenced by the approval of the first "Class III Medical Device" registration certificate for ultrasound aesthetic equipment by the National Medical Products Administration (NMPA) [1][2]. Industry Overview - The approval of the first "Class III Medical Device" certificate marks a significant shift in the medical aesthetics device market, moving towards a high-standard and highly regulated environment [2][4]. - The certification process for Class III medical devices is rigorous, comparable to that of implantable products like pacemakers and artificial joints, requiring comprehensive evidence across the entire product lifecycle [2][3]. Company Insights - The company, Peninsula Medical, has spent over a decade focusing on clinical needs and technology development, positioning itself as a leader in innovation and compliance within the domestic energy source medical aesthetics device sector [1][3]. - Peninsula Medical's commitment to compliance and high standards has allowed it to be one of the few companies to successfully navigate the Class III certification process, having initiated its clinical and registration applications as early as 2021 [3][8]. Market Dynamics - The introduction of the "Class III Medical Device" certificate is expected to reshape market competition and accelerate industry consolidation, with companies that obtain this certification gaining significant advantages in the market [5][12]. - The high technical barriers and market exclusivity associated with the "Class III Medical Device" certification are anticipated to drive revenue growth for certified companies, as downstream medical aesthetic institutions will prioritize products with this certification [5][12]. Technological Advancements - Peninsula Medical has made several original technological breakthroughs, including the "shadow launch technology" and "intelligent ultrasound imaging system," which enhance treatment precision and comfort [7][8]. - The company invests over 25% of its revenue into research and development, employing a large team of nearly 400 R&D personnel, which is among the highest ratios in the industry [7][8]. Global Expansion - Peninsula Medical is expanding its reach into global markets, having received FDA approval for its products and entering prestigious institutions in the United States, reflecting its transition from a domestic equipment manufacturer to a global trusted brand [11][12].